Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer (Q39893964)

15 September 2017

title

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer (English)

1 reference

triple-negative breast cancer

15 September 2017

main subject

0 references

epidermal growth factor receptor

0 references

author name string

B Corkery

1

1 reference

15 September 2017

J Crown

2

1 reference

15 September 2017

M Clynes

3

1 reference

15 September 2017

N O'Donovan

4

1 reference

15 September 2017

publication date

15 January 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

20

1 reference

15 September 2017

issue

5

1 reference

15 September 2017

page(s)

862-867

1 reference

Molecular portraits of human breast tumours

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

EGFR associated expression profiles vary with breast tumor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Gene expression profiling of breast cell lines identifies potential new basal markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

ZD1839 ('Iressa') as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN710

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN710

1 reference

release_ykz26ydq45ffxbuouykksrlvsq

15 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ykz26ydq45ffxbuouykksrlvsq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference